Skip to content

Allergan

Recent events

Recent events tied to this brand in public sources.

Back to profile14 entries

  1. 2024

    Court allows Allergan trade-secrets claims against Revance to proceed

    In Allergan’s trade-secrets lawsuit against competitor Revance, the court denied Revance’s motion to dismiss, finding that alleged access to and similarity involving trade secrets plausibly supported the claims. These are allegations, not a finding of liability.

  2. 2023

    Meituan upgrades medical-aesthetics verification cooperation

    Meituan, the China Association of Plastics and Aesthetics Industry's committee, Allergan and Peninsula Medical upgraded their cooperation on scan-code verification. Meituan said it plans over the next year to place 5,000 verification devices at 1,500 medical-aesthetics institutions.

  3. 2022

    Minnesota states reach tentative opioid settlement with Allergan

    Minnesota Attorney General Keith Ellison announced that multiple states had reached a tentative $2.37 billion settlement agreement with Allergan. The final terms still needed to be reached. Ellison alleged that the companies caused death and destruction by putting profits before people's lives.

  4. 2022

    Teva and Allergan reach San Francisco opioid settlement

    Teva Pharmaceutical Industries and AbbVie's Allergan unit reached a $58 million settlement with San Francisco over claims that they fueled the city's opioid epidemic. Teva will pay $25 million and contribute a $20 million supply of Narcan; AbbVie will pay $13 million. Neither Teva nor Allergan admitted wrongdoing.

  5. 2022

    Florida reaches opioid settlements with CVS Health and drug companies

    Florida reached settlements totaling more than $878 million with CVS Health, Teva Pharmaceutical Industries, Allergan, and Endo International over claims concerning their roles in fueling the state's opioid epidemic. The companies denied wrongdoing in agreeing to settle.

  6. 2021

    Allergan agrees to pay up to $200 million in New York opioid settlement

    Allergan agreed to pay New York state and Nassau and Suffolk counties up to $200 million in a settlement related to its role in the opioid epidemic. The lawsuit claims manufacturers and distributors downplayed addiction risks; the source does not report a court determination of those claims.

  7. 2021

    FDA approves VUITY for presbyopia

    The FDA approved Allergan's VUITY eye drops for the treatment of presbyopia in adults.

  8. 2020

    AbbVie completes acquisition of Allergan

    AbbVie announced that it had completed its acquisition of Allergan; the transaction had received the required government regulatory approvals and approval from the High Court of Ireland.

  9. 2020

    Allergan receives 2020 ENERGY STAR Partner of the Year Sustained Excellence Award

    Allergan announced that it received the 2020 ENERGY STAR Partner of the Year Sustained Excellence Award from the US Environmental Protection Agency, recognizing its energy management and efficiency.

  10. 2020

    Allergan opens biologics facility in Westport

    Allergan opened a €160 million biologics facility at its Westport campus in County Mayo. The company said the expansion would allow it to increase manufacturing of its flagship products and create 63 new jobs.

  11. 2019

    FDA approves Ubrelvy for acute migraine treatment

    The FDA approved Ubrelvy (ubrogepant), marketed by Allergan, for the acute treatment of migraine in adults.

  12. 2019

    Allergan reports third-quarter 2019 results

    Allergan reported third-quarter 2019 financial results, including GAAP net revenues of $4.05 billion, up 3.6 percent from the prior-year quarter.

  13. 2019

    Allergan raises 2019 revenue guidance

    In its third-quarter results announcement, Allergan raised its full-year 2019 net revenue guidance and reaffirmed its guidance for non-GAAP performance net income per share.

  14. 2019

    FDA approves BOTOX for pediatric lower limb spasticity

    The FDA approved Allergan’s supplemental application to expand BOTOX (onabotulinumtoxinA) treatment to pediatric patients aged 2 to 17 with lower limb spasticity, excluding spasticity caused by cerebral palsy.